- Discussion of acromegaly as a model for adult bone growth, with the claim that all adults exhibit a “mild acromegaly” driven by residual growth-hormone signaling.  
- Robert McDougal circulated two new Substack essays: “Superintelligence Now” and “Shrinking the Skull with Cell Therapy,” the latter proposing gene-therapy approaches to reduce skull volume and scar tissue.  
- Exploration of practical routes to obtain research-grade peptides: GsMTx-4 (a tarantula-venom peptide) was highlighted as a candidate to block Piezo1 ion channels and remodel scar tissue; grey-market suppliers (PeptideSciences, Cayman Chemical) and university-lab procurement were compared.  
- Debate on regulatory jurisdictions for human genetic-engineering trials: Próspera (Honduras), Vitalia (Roatán), and other low-regulation zones were weighed against the risks of opaque or hostile governments in parts of Africa and Southeast Asia.  
- Balaji Srinivasan’s recent tweets endorsing “biological intelligence augmentation” and Gene Smith’s LessWrong post on IQ-raising gene therapy were cited as signals of growing elite interest.  
- Skepticism voiced about LessWrong biology posts—praised for references but criticized for overconfident extrapolation—while neuroscience pieces on innate circuit morphogenesis and phasic dopamine were recommended.  
- AllenAI’s Objaverse dataset (10 M high-quality 3-D models with metadata) was noted as a major new resource for vision and robotics research.  
- RocketStar’s p-B11 fusion-boosted electric thruster (≈ 10 cm cube) was presented as an incremental advance in high-efficiency spacecraft propulsion, with discussion of neutron yields and magnetic sails as alternatives.  
- Anecdote shared that biohackers once authored a country’s entire biotech regulation framework because local officials “had no idea where to even start.”